CCR4
C-C chemokine receptor type 4
As of the edition of 20 October 2026, CCR4 (C-C chemokine receptor type 4, UniProt P51679) has 2 drugs tested at it and 3 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P51679
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Cancer; Immune system; Blood and lymph; Lungs and airways; Digestive system; Infections; Mouth and teeth; Nervous system
- Registered trials of its drugs
- 40
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Mogamulizumab | Marketed | Phase 4 | Ends 2030 |
| GSK-2239633 | Went quiet | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Undetermined | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Kyowa Kirin | Route B |
| GSK | Route A |
The other 1 company at CCR4
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at CCR4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.